Literature DB >> 22586039

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Paul Spear1, Amorette Barber, Agnieszka Rynda-Apple, Charles L Sentman.   

Abstract

The infiltration of suppressive myeloid cells into the tumor microenvironment restrains anti-tumor immunity. However, cytokines may alter the function of myeloid lineage cells to support tumor rejection, regulating the balance between pro- and anti-tumor immunity. In this study, it is shown that effector cytokines secreted by adoptively transferred T cells expressing a chimeric Ag receptor (CAR) shape the function of myeloid cells to promote endogenous immunity and tumor destruction. Mice bearing the ovarian ID8 tumor were treated with T cells transduced with a chimeric NKG2D receptor. GM-CSF secreted by the adoptively transferred T cells recruited peripheral F4/80(lo)Ly-6C(+) myeloid cells to the tumor microenvironment in a CCR2-dependent fashion. T cell IFN-γ and GM-CSF activated local, tumor-associated macrophages, decreased expression of regulatory factors, increased IL-12p40 production, and augmented Ag processing and presentation by host macrophages to Ag-specific T cells. In addition, T cell-derived IFN-γ, but not GM-CSF, induced the production of NO by F4/80(hi) macrophages and enhanced their lysis of tumor cells. The ability of CAR T cell therapy to eliminate tumor was moderately impaired when inducible NO synthase was inhibited and greatly impaired in the absence of peritoneal macrophages after depletion with clodronate encapsulated liposomes. This study demonstrates that the activation of host macrophages by CAR T cell-derived cytokines transformed the tumor microenvironment from immunosuppressive to immunostimulatory and contributed to inhibition of ovarian tumor growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22586039      PMCID: PMC3370144          DOI: 10.4049/jimmunol.1103019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

Review 2.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Authors:  Uciane K Scarlett; Juan R Cubillos-Ruiz; Yolanda C Nesbeth; Diana G Martinez; Xavier Engle; Andrew T Gewirtz; Cory L Ahonen; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

Review 4.  The regulation of IL-10 production by immune cells.

Authors:  Margarida Saraiva; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2010-02-15       Impact factor: 53.106

Review 5.  Development of monocytes, macrophages, and dendritic cells.

Authors:  Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley
Journal:  Science       Date:  2010-02-05       Impact factor: 47.728

Review 6.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

7.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Authors:  Jonathan M Weiss; Lisa A Ridnour; Tim Back; S Perwez Hussain; Peijun He; Anna E Maciag; Larry K Keefer; William J Murphy; Curtis C Harris; David A Wink; Robert H Wiltrout
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

8.  Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Authors:  Amorette Barber; Charles L Sentman
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

Review 9.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

10.  Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.

Authors:  Amorette Barber; Agnieszka Rynda; Charles L Sentman
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

View more
  49 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

Review 2.  Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

Authors:  Mingen Liu; Anusha Kalbasi; Gregory L Beatty
Journal:  J Oncol Pract       Date:  2017-03       Impact factor: 3.840

3.  Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Authors:  Marie-Louise Sentman; Joana M Murad; W James Cook; Ming-Ru Wu; Jake Reder; Susanne H Baumeister; Glenn Dranoff; Michael W Fanger; Charles L Sentman
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

Review 4.  NKG2D ligands as therapeutic targets.

Authors:  Paul Spear; Ming-Ru Wu; Marie-Louise Sentman; Charles L Sentman
Journal:  Cancer Immun       Date:  2013-05-01

Review 5.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

6.  NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Authors:  Paul Spear; Amorette Barber; Agnieszka Rynda-Apple; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2013-04-30       Impact factor: 5.126

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 9.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

10.  Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

Authors:  Kyle K Payne; Christine K Zoon; Wen Wan; Khin Marlar; Rebecca C Keim; Mehrab Nasiri Kenari; A Latif Kazim; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2013-10-25       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.